SLBT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 59.54% | Shs Outstand | 560.8M | Perf Week | -28.24% |
| Market Cap | 1.58B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 226.9M | Perf Month | -32.7% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 0.02% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.04 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.06M | Perf YTD | -29.5% |
| Book/sh | - | P/C | - | EPS past 3/5Y | - | ROE | - | 52W High | -80.55% ($14.50) | Perf Year | - |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 0.67% ($2.80) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 12.62% 16.44% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | - | Profit Margin | - | RSI (14) | 44.18 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -32.19% ($4.16) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -35.97% ($4.4) | Rel Volume | 0.09 | Prev Close | $3.12 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -35.97% ($4.4) | Avg Volume(3M) | 1.58M | Price | $2.82 |
| IPO | 2026/6/15 | Option/Short | No/Yes | Trades | 1022 | Volume | 143,111 | Change | -9.62% |
SL Science Holding Ltd (SLBT) Investment Analysis
What kind of company is SL Science Holding Ltd?
🧬 This biotech company, headquartered in Taipei, Taiwan, is listed on NASDAQ and is engaged in two key areas: skincare products based on exosomes and plant extracts, and cell therapy research focused on gamma-delta T cells. The company generates revenue from its cosmetics business while simultaneously advancing a cell therapy pipeline targeting solid tumors.
Key Events
SLBT의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.
- 실적 발표는 보통 분기마다 있습니다
- 배당주는 연 1~4회 배당락일이 있습니다
Is it profitable?
Profitability and financial-health indicators have not yet been collected.
What's the outlook?
Analyst estimates and price targets have not been collected.
Did earnings meet expectations?
No analyzable past earnings releases have been collected yet.
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 28-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $2.82 below the midline ($4.16). Normal downward flow.
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 25.2 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 8.8.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Key metrics such as PER and PBR are unavailable, so valuation is omitted.
Who owns it?
How much does it pay in dividends?
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| SLBT This Stock | $1.6B | - | - | - | - | -9.6% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is SLBT?
SLBT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLBT?
The market cap of SLBT is approximately $1.6B, ranking 2,295 within its sector.
What is the 52-week high and low for SLBT?
SLBT has recorded a 52-week high of $14.50 and a low of $2.80.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.